The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 17.25 million shares traded hands or 656.58% up from the average. Concordia International Corp (NASDAQ:CXRX) has declined 87.26% since April 5, 2016 and is downtrending. It has underperformed by 89.22% the S&P500.
The move comes after 7 months negative chart setup for the $162.74M company. It was reported on Nov, 7 by Barchart.com. We have $1.78 PT which if reached, will make NASDAQ:CXRX worth $17.90M less.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 earnings per share, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $109.85 million for 0.37 P/E if the $1.35 EPS becomes a reality. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was maintained by Scotia Capital on Tuesday, September 29 with “Sector Outperform”. The stock of Concordia International Corp (NASDAQ:CXRX) has “Neutral” rating given on Monday, August 15 by Goldman Sachs. Scotia Capital maintained Concordia International Corp (NASDAQ:CXRX) rating on Friday, October 16. Scotia Capital has “Sector Outperform” rating and $75 price target. The rating was initiated by IBC on Monday, November 30 with “Sector Perform”. The rating was maintained by S&P Research with “Buy” on Friday, October 16. The stock of Concordia International Corp (NASDAQ:CXRX) has “Sector Perform” rating given on Monday, September 19 by Scotia Capital. Laurentian maintained the shares of CXRX in a report on Tuesday, March 29 with “Buy” rating. The rating was downgraded by GMP Securities on Monday, August 15 to “Hold”. Goldman Sachs initiated Concordia International Corp (NASDAQ:CXRX) rating on Monday, June 6. Goldman Sachs has “Neutral” rating and $32 price target. As per Monday, August 15, the company rating was downgraded by IBC.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: Business.Financialpost.com which released: “Concordia International shares plummet to record low after drugmaker suspends …” on November 07, 2016, also Prnewswire.com with their article: “Concordia International Corp. Announces Communication With CMA” published on October 25, 2016, Prnewswire.com published: “Concordia International Corp. Announces CEO Transition Plan” on October 21, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: Marketwatch.com and their article: “Concordia International Corp. Announces Second Cross Currency Swap Agreement” published on November 01, 2016 as well as Prnewswire.com‘s news article titled: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX” with publication date: August 17, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.